Off-label use of atypical antipsychotics: Cause for concern?

CNS Drugs

Volumn 26, Issue 5, 2012, Pages 383-390

  McKean, Andrew ^a   Monasterio, Erik ^b  

^a PRINCESS MARGARET HOSPITAL   (New Zealand)

^b Hillmorton Hospital   (New Zealand)

Author keywords

Antipsychotics; Bipolar disorders; Dementia; Elderly; Mortality; Psychotic disorders; Quetiapine; Schizophrenia; Type 2 diabetes mellitus; Weight gain

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CITALOPRAM; LINEZOLID; OLANZAPINE; PREGABALIN; QUETIAPINE; RISPERIDONE; VALDECOXIB; ZIPRASIDONE;

AGE DISTRIBUTION; ANXIETY DISORDER; BIPOLAR DISORDER; DEMENTIA; DRUG ABUSE; DRUG EFFICACY; DRUG INDUSTRY; DRUG MEGADOSE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSESSIVE COMPULSIVE DISORDER; OFF LABEL DRUG USE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SUDDEN DEATH; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; COMMERCE; DRUG INDUSTRY; DRUG LABELING; HUMANS; OFF-LABEL USE; PHYSICIAN'S PRACTICE PATTERNS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84860003257     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11632030-000000000-00000     Document Type: Review

References (50)

1. Healy D, Nutt D. Prescriptions, licenses and evidence. Psychiatr Bull 1998;22: 680-4
2. Avorn J, Kesselheim A. A hemorrhage of off-label use. Ann Intern Med 2011;154 (8): 566-7
3. Radley DC, Finkelstein MD, Randall S, et al. Off-label prescribing among office-based physicians. Arch Int Med 2006;166: 1021-6
4. Pickar D, Vinik J, Bartko J. Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use. PLoS 2008;3: 9 e150
5. Chakos MH, Glick ID, Miller AL, et al. Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 2006;57: 1094-101 (Pubitemid 44204901)
6. Leslie D, Mohamed S, Rosenheck R. Off label use of antipsychotic medications in the department of Veterans Affairs health care system. Psychiatr Serv 2009;60 (9): 1175-81
7. Haw C, Stubbs J. A survey of the off-label-use of mood stabilizers in a large psychiatric hospital. J Psychopharmacol 2005;19: 402-7 (Pubitemid 41003137)
8. Martin-Latry K, Ricard C, Verdoux H. A one-day survey of characteristics of off-label hospital prescription of psychotropic drugs. Pharmacopsychiatry 2007;40 (3): 116-20 (Pubitemid 46910383)
9. Hampton T. Experts weigh in on promotion, prescription of off-label drugs. JAMA 2007;297 (7): 683-4 (Pubitemid 46294577)
10. Kuehn B. FDA panel issues mixed decision on quetiapine in depression and anxiety. JAMA 2009;301 (20): 2081-2
11. Maglione M, MaherA, Shekelle P, et al. Off-label use of atypical antipsychotics: an update [online].Available fromURL: www. effectivehealthcare. ahrq.gov/ehc/products/150/786/CER43-Off-LabelAntipsychotics-execsumm-20110928. pdf [Accessed 2011 Sep 28]
12. Electronic Medicines Compendium (eMC) [online]. Available from URL: http://www.medicines.org.uk [Accessed 2012 Mar 8]
13. Risperidone: New Zealand data sheet, updated 26 August 2010 [online]. Available from URL: www.medsafe.govt.nz [Accessed 2011 Oct 8]
14. Maher A, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off label uses in adults: a systematic review and metaanalysis. JAMA 2011;306 (12): 1359-69
15. Fountoulakis KN, Nimatoudis I, Lacovides A, et al. Off label indications for atypical antipsychotics: a systematic review. Ann Gen Hosp Psychiatry 2004;3: 4 [online]. Available from URL: http://www.general-hospital-psychiatry. com/content/3/1/4 [Accessed 2012 Feb 29]
16. Kesselheim A, Mello M, Studdert D. Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. PLoS Med 2011;8 (4): e1000431
17. Newman M. Bitter pills for drug companies. BMJ 2010;341: c5095
18. Hopkins Tanne J. AstraZeneca pays $520m fine for off label marketing. BMJ 2010;340: c2380
19. Kmietowicz Z. Eli Lilly pays record $1.4bn for promoting off-label use of olanzapine. BMJ 2009;338: b217
20. Stafford R. Regulating off-label drug use: rethinking the role of the FDA. N Engl J Med 2008;358 (14): 1427-9 (Pubitemid 351482734)
21. Kesselheim AS, Studdert DM, Mello MM. Whistle-blowers' experiences in fraud litigations against pharmaceutical companies. N Engl J Med 2010;362: 1832-9
22. Kendall T. The rise and fall of the atypical antipsychotics. Br J Psychiatry 2011;199: 266-8
23. Tanne JH. FDA oversight of drug company promotion of off label use is poor, US watchdog says. BMJ 2008;337: a1163
24. Gagnon MA, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med 2008;1 (5): 29-33
25. Crystal S, Olfson M, Huang C, et al. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Affairs 2009;28 (5): w770-81
26. Ashcroft DM, Frischer M, Lockett S, et al. Variations in prescribing atypical antipsychotic drugs in primary care: cross-sectional study. Pharmacoepidemiol Drug Saf 2002;11: 285-9 (Pubitemid 34704728)
27. Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf 2011;20 (2): 177-84
28. Kalverdijk LJ, Tobi H, van den Berg PB, et al. Use of antipsychotic drugs among Dutch youths between 1997 and 2005. Psychiatr Serv 2008;59: 554-60
29. Top 20 global therapeutic products 2010, total audited markets [online]. Available from URL: www.imshealth. com [Accessed 2011 Aug 16]
30. Kuehn B. Questionable antipsychotic prescribing remains common despite serious risks. JAMA 2010;303 (16): 1582-4
31. Monasterio E, McKean A. Off-label use of atypical antipsychotic medications in Canterbury, New Zealand. N Z Med J 2011;124 (1336): 24-9
32. Sankaranarayanan J, Puumala S. Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996-2003: national estimates and associated factors. Clin Ther 2007;29 (4): 723-41 (Pubitemid 47018273)
33. Comer J, Mojtabai R, Olfson M. National trends in the antipsychotic treatment of psychiatric outpatients with anxiety disorders. Am J Psychiatry 2011;168: 1057-65
34. Kamble P, Sherer J, Chen H, et al. Off-label use of second generation antipsychotic agents among elderly nursing home residents. Psychiatr Serv 2010;61 (2): 130-6
35. Tiller J, Ames D, Brodaty H, et al. Antipsychotic use in the elderly: what doctors say they do, and what they do. Aust J Ageing 2008;27 (3): 134-42
36. Kales HC, Zivin K, Kim HM, et al. Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry 2011;68 (2): 190-7
37. Domino M, Swartz M. Who are the new users of antipsychotic medicines? Psychiatr Serv 2008;59 (5): 507-14
38. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year followup of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374 (9690): 620-7
39. Trifiro G, Gambassi G, Sen E, et al. Association of community acquired pneumonia with antipsychotic drug use in elderly patients. Ann Intern Med 2010;152: 418-25
40. Pratt N, Roughead E, Ramsay E, et al. Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly. Drug Saf 2011;34 (7): 567-75
41. Dorsey E, Rabanni A, Gallagher S, et al. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med 2010;170 (1): 96-103
42. CatesM, JacksonC, Feldman J, et al.Metabolic consequences of using low dose quetiapine for insomnia in psychiatric patients. Community Ment Health J 2009;45: 251-4
43. Brecher M, Leong R, Stening G, et al. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. J Clin Psychiatry 2007;68 (4): 597-603 (Pubitemid 46663043)
44. Kessing L, Thomsen A, Mogensen U, et al. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 2010;197: 266-71
45. Ray W, Chung C, Murray K, et al. Atypical antipsychotics and the risk of sudden cardiac death. New Engl J Med 2009;360 (3): 225-35
46. Pierre JM, Shnayder I, Wirshing DA, et al. Intranasal quetiapine abuse [letter]. Am J Psychiatry 2004;161: 1718
47. Hussain MZ, Waheed W, Hussain S. Intravenous quetiapine abuse [letter]. Am J Psychiatry 2005;162: 1755-6
48. Hanley M, Kenna G. Quetiapine: treatment for substance abuse and drug of abuse. Am J Health Syst Pharm 2008;65 (1): 611-8 (Pubitemid 351490694)
49. Waters BM, Joshi KG. Intravenous quetiapine-cocaine use ('Q-ball') [letter]. Am J Psychiatry 2007;164: 173-4 (Pubitemid 46154807)
50. Pinta ER, Taylor RE. Quetiapine addiction? [letter]. Am J Psychiatry 2007;164: 174